New class of agents for treatment of hypertension: focus on direct renin inhibition

References

• FyhrquistFSaijonmaaORenin-angiotensin system revisitedJ Intern Med200826422423618793332
   PubMed Web of Science ®Google Scholar
• CesariMRossiGPPessinaACBiological properties of the angiotensin peptides other than angiotensin II: Implications for hypertension and cardiovascular diseasesJ Hypertens20022079379912011628
   PubMedGoogle Scholar
• Dan JanserAHBatenburgWvan EschJHProrenin and the (pro)renin receptor – an updateNephrol Dial Transplant2007221288129217259648
   PubMed Web of Science ®Google Scholar
• AtlasSAThe renin-angiotensin-aldosterone system: Pathophysiological role and pharmacologic inhibitionJ Manag Care Pharm200713Suppl B92017970613
   PubMedGoogle Scholar
• WeberMAGilesTDInhibiting the renin-angiotensin system to prevent cardiovascular disorders: Do we need a more comprehensive strategyRev Cardiovasc Med20067455416915123
   PubMed Web of Science ®Google Scholar
• AbassiZWinaverJFeuersteinGZThe biochemical pharmacology of renin inhibitors: Implications for translational medicine in hypertension, diabetic nephropathy and heart failure: Expectations and realityBiochem Pharmacol20097893394019477166
   PubMed Web of Science ®Google Scholar
• JensenCHeroldPBrunnerHRAliskiren: The first renin inhibitor for clinical treatmentNat Rev Drug Discov2008739941018340340
   PubMed Web of Science ®Google Scholar
• WoodJMMaibaumJRahuelJStructure-based design of aliskiren, a novel orally effective renin inhibitorBiophys Res Commun2003308698705
   PubMed Web of Science ®Google Scholar
• RashidHDirect renin inhibition:an evaluation of the safety and tolerability of aliskirenCurr Med Res Opin2008242627263718687166
   PubMed Web of Science ®Google Scholar
• WaldmeierFGlaenzelUWirzBAbsorption, distribution, metabolism and elimination of the direct renin inhibitor aliskiren in healthy volunteersDrug Metab Dispos2007351418142817510248
   PubMed Web of Science ®Google Scholar
• ZhaoCVaidyanathanSYehCMAliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with Type 2 diabetes mellitusClin Pharmacokinet2006451125113417048976
   PubMed Web of Science ®Google Scholar
• VaidyanathanSWarrenVYehCPharmacokinetics, safety and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairmentJ Clin Pharmacol20074719220017244770
   PubMed Web of Science ®Google Scholar
• SealeyJELaraghJHAliskiren, the first renin inhibitor for treating hypertension: Reactive secretion may limit its effectivenessAm J Hypertens20072058759717485026
   PubMed Web of Science ®Google Scholar
• FeldmanDLJinLXuanHEffects of aliskiren on blood pressure, albuminuria and (pro)renin receptor expression in diabetic TG(mRen-2) ratsHypertension20085213013618490518
   PubMed Web of Science ®Google Scholar
• GradmanAHPintoRKadRCurrent concepts: Renin inhibition in the treatment of hypertensionCurr Opin Pharmacol2008812012618308634
   PubMed Web of Science ®Google Scholar
• MenardJGuyeneTTPeyrardSAziziMConformational changes in prorenin inhibition in vitro and in vivoJ Hypertens20062452953416467656
   PubMed Web of Science ®Google Scholar
• StantonAJensenCMannJO’BrienEBlood pressure lowering with SPP100, a novel orally active renin inhibitor: A pilot studyHypertension 200138526
   Web of Science ®Google Scholar
• StantonAJensenCNussbergerJO’BrienEBlood pressure lowering in essential hypertension with an oral renin inhibitor, aliskirenHypertension2003421137114314597641
   PubMed Web of Science ®Google Scholar
• GradmanAHSchiemerRELinsRLNussbergerJChiangYBadigianMPAliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patientsCirculation20051111012101815723979
   PubMed Web of Science ®Google Scholar
• KushiroTItakuroHAboYAliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertensionHypertens Res200629997100517378372
   PubMed Web of Science ®Google Scholar
• OhBHMitchellJHerronJRAliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertensionJ Am Coll Cardiol2007491157116317367658
   PubMed Web of Science ®Google Scholar
• PoolJLGradmanAKollochRAliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertensionEur Heart J 20062711916278228
   PubMed Web of Science ®Google Scholar
• PalatiniPWungWShlyakhtoEBothaJBushCKeefeDLMaintenance of blood-pressure lowering effect following a missed dose of aliskiren, irbesartan or ramipril: Results of a randomized, double-blind studyJ Hum Hypertens2010249310319458624
   PubMed Web of Science ®Google Scholar
• VillamilAChrysantSGCalhounDRenin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazideJ Hypertens20072521722617143194
   PubMed Web of Science ®Google Scholar
• SchmiederREPhilippTGuerediagaJLong-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: A 12-month randomized, double-blind comparator trial with hydrochlorothiazideCirculation200911941742519139391
   PubMed Web of Science ®Google Scholar
• UresinYTaylorAAKiloCEfficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertensionJ Renin Angiotensin Aldosterone Syst2007819019818205098
   PubMed Web of Science ®Google Scholar
• AndersenKWeinbergerMHEganBComparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind trialJ Hypertens20082658959918300872
   PubMed Web of Science ®Google Scholar
• DuprezDAMungerMABothaJAliskiren for geriatric lowering of systolic hypertension: A randomized, controlled trialJ Hum Hypertens12242009 [Epub ahead of print]
   Web of Science ®Google Scholar
• StrasserRHPuigJGFarsangCA comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertensionJ Hum Hypertens20072178078717541390
   PubMed Web of Science ®Google Scholar
• OparilSYarowsSAPatelSEfficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomized, double-blind trialLancet200737022122917658393
   PubMed Web of Science ®Google Scholar
• PoolJLSchmiederREAziziMAliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartanAm J Hypertens200720112017198906
   PubMed Web of Science ®Google Scholar
• SolomonSDAppelbaumEManningWJAliskiren in Left Ventricular Hypertrophy (ALLAY) Trial InvestigatorsEffect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophyCirculation200911953053719153265
   PubMed Web of Science ®Google Scholar
• DrummondWMungerMARafique EssopMAntihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapyJ Clin Hypertens20079742750
   PubMedGoogle Scholar
• FogariRMugelliniAPretiPEffect of aliskiren addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patientsJ Hypertens201028e-Supp A PP 5.183 e 102
   Google Scholar
• LittlejohnTW3rdTrenkwalderPHollandersGLong-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertensionCurr Med Res Opin20092595195919257800
   PubMed Web of Science ®Google Scholar
• TaylorATschopeDKiloCAdding aliskiren to ramipril improves 24-hour blood pressure control compared to ramipril alone in patients with diabetes and hypertensionJ Hypertens200624Suppl 48182
   Google Scholar
• YarrowsSAOparilSPatelSAliskiren in combination with valsartan provides superior 24-hour ambulatory blood pressure reductions compared with either agent alone in patients with hypertensionJ Clin Hypertens200795 Suppl A188189
   Google Scholar
• WeirMBushCAndersonDZhangJKeefeDSatlinAAntihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: A pooled analysisJ Am Soc Hypertens2007126427720409858
   PubMed Web of Science ®Google Scholar
• SolomonSDEffect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with left ventricular dysfunction: ASPIREPresented at: American College of Cardiology 59th Annual Scientific SessionsAtlanta, GAMar 13–16, 2010
   Google Scholar
• SelbyJVPengTKarterAJHigh rates of occurrence of hypertension, elevated low-density lipoprotein cholesterol and diabetes mellitusAm J Manag Care20041016317015005509
   PubMed Web of Science ®Google Scholar
• TaylorAAAndersonDRAroraVAntihypertensive efficacy, safety and tolerability of the oral direct inhibitor aliskiren in patients with diabetes: A pooled analysis of 10 randomized trials67th Annual Scientific Session of ADAChicago, ILJun 22–26, 2007
   Google Scholar
• BramlagePPittrowDWittchenHUHypertension in overweight and obese primary care patients is highly prevalent and poorly controlledAm J Hypertens20041790491015485752
   PubMed Web of Science ®Google Scholar
• JordanJEngeliSBoyeSWLe BretonSKeefeDLDirect renin inhibition with aliskiren in obese patients with arterial hypertensionHypertension2007491047105517353513
   PubMed Web of Science ®Google Scholar
• SchmiederREPhilippTGuerediagaJGorostidiMBushCKeefeDLAliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: Subanalysis of a 52-week, randomized, double-blind trialJ Hypertens2009271493150119444142
   PubMed Web of Science ®Google Scholar
• KroneWHanefeldMMeyerHFComparative efficacy and safety of aliskiren and irbesartan in patients with metabolic syndromeJ Hum Hypertens482010 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• FogariRDifferent effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndromeHormon. Metab. Res2010in Press
   Web of Science ®Google Scholar
• VerdecchiaPCalvoCMockelVKeelingLSatlinASafety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertensionBlood Press20071638139118058456
   PubMed Web of Science ®Google Scholar
• ASPIRE HIGHER clinical program expands to 35,000 patients in 14 trials, the largest cardio-renal outcomes program ever Available from: http://www.novartis.be/downloads/nl/pers-media/berichten/reports/2008-07-17_financial-report_s1-2008_en.pdfAccessed on Jun 25, 2010
   Google Scholar
• PilzBShagdarsurenEWellnerMAliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic ratsHypertension20054656957616103264
   PubMed Web of Science ®Google Scholar
• DecherdRShagdarsrenEGratzePLow-dose renin-inhibitor and low-dose AT1-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genesJ Renin Angiotensin Aldosterone Syst20078818417703434
   PubMed Web of Science ®Google Scholar
• WestermannDRiadALettauORenin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressureHypertension2008521068107518955663
   PubMed Web of Science ®Google Scholar
• SeedAGardnerRMcMurrayJNeurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failureEur J Heart Fail200791120112717945530
   PubMed Web of Science ®Google Scholar
• McMurrayJPittBLatiniREffects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failureCirc Heart Fail20081172419808266
   PubMed Web of Science ®Google Scholar
• LatiniRMassonSAnandIEffects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The Valsartan Heart Failure Trial (Val-HeFT)Circulation20021062454245812417542
   PubMed Web of Science ®Google Scholar
• ManciniGBDahlofBDiezJSurrogate markers for cardiovascular disease: Structural markersCirculation2004109IV22IV3015226248
   PubMed Web of Science ®Google Scholar
• The ONTARGET InvestigatorsTelmisartan, ramipril or both in patients at high risk for vascular eventsNew Engl J Med20083581547155918378520
   PubMed Web of Science ®Google Scholar
• KellyDJZhangYMoeGNaikGGilbertREAliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in ratsDiabetologia2007502398240417828524
   PubMed Web of Science ®Google Scholar
• PerssonFRossingPSchjoedtKJTime course of the antiproteinuric and antihypertensive effects of direct renin inhibition in Type 2 diabetesKidney Int2008731419142518337712
   PubMed Web of Science ®Google Scholar
• ParvingHHPerssonFLewisJBLewisEJHollengergNHAliskiren combined with losartan in Type 2 diabetes and nephropathyN Engl J Med20083582433244618525041
   PubMed Web of Science ®Google Scholar
• PerssonFRossingPReinhardHRenal effects of aliskiren compared with and in combination with irbesartan in patients with Type 2 diabetes, hypertension and albuminuriaDiabetes Care2009321873187919587362
   PubMed Web of Science ®Google Scholar
• FischerNDJanDanserAHNussbergerJDoleWPHollenbergNKRenal and hormonal responses to direct renin inhibition with aliskiren in healthy humansCirculation20081173199320518559696
   PubMed Web of Science ®Google Scholar
• NussbergerJAubertJFBouzoureneKPellegrinMHayozDMazzolaiLRenin inhibition by aliskiren prevents atherosclerosis progression: Comparison with irbesartan, atenolol, and amlodipineHypertension2008511306131118391092
   PubMed Web of Science ®Google Scholar
• ImanishiTTsujiokaHIkejimaHRenin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changesHypertension20085256357218645051
   PubMed Web of Science ®Google Scholar
• DongYFLiuLKataokaKAliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and Type 2 diabetesDiabetologia20105318019119894030
   PubMed Web of Science ®Google Scholar
• InoJKojimaCOsakaMNittaKYoshidaMDynamic observation of mechanically-injured mouse femoral artery reveals an anti-inflammatory effect of renin inhibitorArterioscler Thromb Vasc Biol2009291858186319778947
   PubMed Web of Science ®Google Scholar
• CherneyDZLaiVScholeyJWMillerJAZinmanBReichHNThe effect of direct renin inhibition on renal haemodynamic function, arterial stiffness and endothelial function in humans with uncomplicated Type 1 diabetes mellitus: A pilot studyDiabetes Care20103336136519889802
   PubMed Web of Science ®Google Scholar
• SeverPSGradmanAHAziziMManaging cardiovascular and renal risk: The potential of direct renin inhibitionJ Renin Angiotensin Aldosterone Syst200910657619502253
   PubMed Web of Science ®Google Scholar
• ParvingHHBrennerBMMcMurrayJJAliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study designNephrol Dial Transplant2009241663167119145003
   PubMed Web of Science ®Google Scholar